Authors : Dr. Luis Gómez Peña

Volume/Issue : Volume 11 - 2026, Issue 4 - April

Google Scholar : https://tinyurl.com/3abs7c7h

Scribd : https://tinyurl.com/bducctde

DOI : https://doi.org/10.38124/ijisrt/26apr174

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : The Integrated Multi-Axis Model of Organ-Metabolic Dysfunction (MIDOM) is proposed as an innovative approach to understanding the early progression of low-grade systemic inflammation before established organ damage, integrating the intestinal, metabolic, inflammatory, and hemodynamic axes. The general objective of the study is to develop and substantiate an integrative clinical model that allows for the early identification of subclinical biological dysfunction and improves intervention capacity in primary care. Methodologically, it is based on an integrative theoretical review of recent evidence, articulating functional and biochemical biomarkers at progressive levels of pathophysiological alteration, organized in a multi-axis system with sequential and relational logic. The main results show that initial intestinal dysfunction, expressed by alterations in the mucosal barrier, is associated with the development of insulin resistance and, subsequently, with systemic inflammatory activation and endothelial dysfunction, configuring a dynamic and bidirectional process. Furthermore, a positive feedback loop is identified between these axes that amplifies the progression of metabolic damage. In conclusion, the MIDOM model offers a solid and clinically applicable conceptual framework for the early detection of low-grade systemic inflammation, with the potential to improve medical decision-making, optimize preventive strategies, and serve as a basis for future clinical validations and technological developments in health.

Keywords : Low-Grade Systemic Inflammation, Insulin Resistance, Intestinal Permeability, Endothelial Dysfunction, Clinical Biomarkers.

References :

1. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19(1):55-71.
2. Raaj I, Thalamati M, Gowda MNV, et al. The role of the plasma atherogenic index and the Castelli I and
3. II risk indices in assessing cardiovascular disease risk in different obesity subtypes: a cross-sectional study. Cureus. 2024;16(11): e74644. doi:10.7759/cureus.74644.
4. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2023 guidelines for the management of overweight and obesity. Circulation. 2023;147(15):e722-e746.
5. Kosmas CE, Bousvarou MD, Kostara CE, Papakonstantinou EJ, Salamou E, Guzman E. Insulin resistance and cardiovascular disease. J Int Med Res. 2023;51(3):3000605231164548. doi:10.1177/03000605231164548.
6. Li T, et al. Inflammation and insulin resistance in diabetic patients with chronic coronary syndrome. Nutrients. 2023;15(12):2808.
7. Sun Y, Deng W, Wang H, Chen M. The mediation of systemic inflammation in insulin resistance and prognosis in ischemic stroke. Front Neurol. 2025; 16:1580862.
8. Sun Y, Liu B, Chen Y, Zhang X, Wang J. Systemic inflammation mediates the relationship between insulin resistance and adverse clinical outcomes: evidence from NHANES 2005-2018. Front Endocrinol (Lausanne). 2025; 16:1298745. doi:10.3389/fendo.2025.1298745.
9. Hotamisligil GS. Inflammation, meta-inflammation and immunometabolic disorders. Nature. 2022;542(7640):177-85.
10. Karaca Y, Karasu M, Gelen MA, et al. Systemic immune inflammatory index as a predictor of blood pressure variability in adults with newly diagnosed hypertension. J Clin Med. 2024;13(22):6647.
11. Zhang X, Wei R, Wang X, et al. The neutrophil/lymphocyte ratio is associated with all-cause and cardiovascular mortality in individuals with hypertension. Cardiovasc Diabetol. 2024; 23:117.
12. Mazidi M, Katsiki N, Mikhailidis DP, Banach M. A lower neutrophil-to-lymphocyte ratio is associated with a lower risk of cardiovascular events. J Clin Med. 2021;10(9):1935.
13. Schinzari F, Tesauro M, Cardillo C. Endothelial dysfunction: pathophysiology and clinical implications. Eur Heart J. 2022;43(24):2336-48.
14. Pallarés-Carratalá V, Ruiz-García A, Serrano-Cumplido A, et al. Prevalence rates of arterial hypertension according to threshold criteria of 140/90 or 130/80 mmHg and associated cardiometabolic and renal factors: SIMETAP-HTN Study. Medicina (Kaunas). 2023;59(10):1846.
15. Oikonomou EK, Antoniades C. The role of precision medicine in cardiometabolic diseases. Eur Heart J. 2023;44(6):489-501.